Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis

Acta Haematologica

Volumn 109, Issue 3, 2003, Pages 111-118

  Caillot, D ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Amphotericin B; Aspergillosis; Itraconazole

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMOPTYSIS; HUMAN; LONG TERM CARE; LUNG ASPERGILLOSIS; LUNG EDEMA; MALE; MYCOSIS; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ITRACONAZOLE; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED;

EID: 0037275689     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069281     Document Type: Article

References (33)

1. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nübling G, Huebner K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
2. Manual RJ, Kibbler CC: The epidemiology and prevention of invasive aspergillosis. J Hosp Infect 1998;39:95-109.
3. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S, Naoe S, Okudaira M, Scevola D, van't Wout J: Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109.
4. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP: Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: A 9-year study. J Clin Oncol 1991;9:77-84.
5. Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases. Rev Infect Dis 1990;12:1147-1202.
6. Lortholary O, Ascioglu S, Moreau P, Herbrecht R, Marinus A, Casassus P, De Pauw B, Denning DW: Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: A European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. Clin Infect Dis 2000;30:41-46.
7. Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-329.
8. Reents S, Goodwin SD, Singh V: Antifungal prophylaxis in imunocompromised hosts. Ann Pharmacother 1993;27:53-60.
9. Working Party of the British Society for Antimicrobial Chemotherapy. Therapy of deep fungal infection in haematological malignancy. J Antimicrob Chemother 1997;40:779-788.
10. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ: Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396.
11. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS, National Institute of Allergy and Infectious Diseases Mycoses Study Group: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-771.
12. Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC: Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000;25:879-884.
13. Ringden O, Jonsson V, Hansen M, Tollemar J, Jacobsen N: Severe and common side-effects of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1998;22:733-734.
14. Boogaerts M, Tormans G, Maes E, Van Doorslaer B: Cost-effectiveness analysis of Ambisome (AMB) vs amphotericin B (AMPHOB) in the empiric treatment of febrile neutropenia in adults and children. Blood 1996;88(suppl 1):501a.
15. Annemans L, Moeremans K, Milligan DW, Kibbler C, Van Gool R: Economic evaluation of intravenous itraconazole in presumed systemic fungal infections. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999.
16. Verweij PE, Bos JJ, Severens JL, Donnelly JP, De Pauw BE, Meis JFGM: Cost-effectiveness of liposomal amphotericin B for the treatment of invasive fungal infections in neutropenic patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 1998.
17. van't Wout JW, Novakova I, Verhagen CA, Fibbe WE, de Pauw Be, van der Meer JW: The efficacy of itraconazole against systemic fungal infections in neutropenic patients: A randomised comparative study with amphotericin B. J Infect 1991;22:45-52.
18. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-147.
19. Boogaerts MA, Maertens J, Van Der Geest R, Bosly A, Michaux JM, Van Hoof A, Cleeren M, Wostenborghs R, De Beule K: Pharmacokinetics and safety of 7 days on intravenous itraconazole followed by 14 days of itraconazole oral solution in patients with hematological malignancy. Antimicrob Agents Chemother 2001;45:981-985.
20. Vandewoude K, Vogelaers D, Decruyenaere J, Jaqmin P, De Beule K, Van Peer A, Woestenborghs R, Groen K, Colardyn F: Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997;41:2714-2718.
21. Zhou H, Goldman M, Wu J, Woestenborghs R, Hassell AE, Lee P, Baruch A, Pesco-Koplowitz L, Borum J, Wheat LJ: A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 1998;38:593-602.
22. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001;33:e83-e90.
23. Dupont B: Intraconazole therapy in aspergillosis: Study in 49 patients. J Am Acad Dermatol 1990;23:607-614.
24. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, et al: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-144.
25. Stevens DA, Lee JY: Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997;157:1857-1862.
26. Schaffner A, Bohler A: Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism. Mycoses 1993;36:421-424.
27. Popp AI, White MH, Quadri T, Walshe L, Armstrong D: Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study. Int J Infect Dis 1999;3:157-160.
28. Daneshmend TK, Warnock DW: Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983;8:17-42.
29. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K: Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels. Mycoses 1989;32(suppl 1):103-108.
30. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL: Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-247.
31. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, Schmidt-Wolf IG: Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999;42:443-451.
32. Prentice AG, Warnock DW: Itraconazole more bioavailable in solution (letter). Blood 1996;88:3662-3663.
33. Persat F, Schwartzbrod PE, Troncy J, Timour Q, Maul A, Piens MA, Picot S: Abnormalities in liver enzymes during simultaneous therapy with itraconazole and amphotericin B in leukaemic patients. J Antimicrob Chemother 2000;45:928-929.